DNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ginkgo Bioworks Holdings Inc (DNA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak financial performance, bearish technical indicators, and lacks significant positive catalysts. While analysts maintain a Buy rating, the reduced price target and negative sentiment from recent earnings suggest caution. Holding off on investment until clearer growth trends emerge is recommended.
The technical indicators for DNA are bearish. The MACD histogram is negative and contracting, RSI is neutral at 30.473, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 6.74, with resistance at 9.313. The stock is trading near its support level, indicating potential downside risk.
Analysts maintain a Buy rating, citing potential for multi-year growth frameworks and sector recovery. The strategic pivot towards robotics could provide long-term growth opportunities.
The announcement of selling the biosecurity business and the pivot towards robotics raised concerns about future growth. Hedge funds and insiders show neutral sentiment, and there is no recent congress trading data to indicate confidence in the stock.
In 2025/Q3, revenue dropped by 56.39% YoY to $38.84 million. Net income improved but remains negative at -$80.76 million, up 43.18% YoY. EPS increased to -1.45, up 34.26% YoY, and gross margin dropped to 67.04%, down 22.52% YoY. The financials indicate weak growth trends and ongoing losses.
TD Cowen lowered the price target from $14 to $12 but maintained a Buy rating. Analysts are optimistic about stocks with clear multi-year growth frameworks, but the reduced price target reflects caution.
